LeMaitre Vascular, Inc. Stock

Equities

LMAT

US5255582018

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
63.04 USD -1.68% Intraday chart for LeMaitre Vascular, Inc. -6.01% +11.06%
Sales 2024 * 212M Sales 2025 * 227M Capitalization 1.41B
Net income 2024 * 37M Net income 2025 * 41M EV / Sales 2024 * 6.68 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 6.23 x
P/E ratio 2024 *
38.1 x
P/E ratio 2025 *
34.2 x
Employees 622
Yield 2024 *
1.02%
Yield 2025 *
-
Free-Float 83.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.68%
1 week-6.01%
Current month-5.00%
1 month-5.69%
3 months+10.77%
6 months+28.68%
Current year+11.06%
More quotes
1 week
63.04
Extreme 63.04
65.46
1 month
63.04
Extreme 63.04
68.14
Current year
52.88
Extreme 52.88
74.64
1 year
44.27
Extreme 44.27
74.64
3 years
38.32
Extreme 38.32
74.64
5 years
18.76
Extreme 18.76
74.64
10 years
6.48
Extreme 6.48
74.64
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 92-05-31
President 59 96-12-31
Director of Finance/CFO 59 04-12-31
Members of the board TitleAgeSince
Director/Board Member 58 14-04-08
Director of Finance/CFO 59 04-12-31
Director/Board Member 76 08-09-16
More insiders
Date Price Change Volume
24-04-17 63.04 -1.68% 59,280
24-04-16 64.12 -0.51% 54,234
24-04-15 64.45 -0.31% 80,610
24-04-12 64.65 -1.54% 99,549
24-04-11 65.66 -2.10% 103,959

Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT

More quotes
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
63.04 USD
Average target price
71.29 USD
Spread / Average Target
+13.08%
Consensus